
**Claims**:

1. The use of a compound of formula (I), or a salt, hydrate, solvate or N-oxide thereof, in the preparation of an antibacterial composition:



(I)

wherein:

**m** is 0 or 1;

**Q** is hydrogen or cyclopropyl;

**Alk** is an optionally substituted, divalent $C_1$-$C_6$ alkylene, alkenylene or alkynylene radical which may contain an ether (-O-), thioether (-S-) or amino (-NR)- link, wherein **R** is hydrogen, -CN or $C_1$-$C_3$ alkyl;

**X** is -C(=O)$NR_6$-, -S(O)$NR_6$-, -C(=O)O- or -S(=O)O- wherein $R_6$ is hydrogen, optionally substituted $C_1$-$C_6$ alkyl, $C_2$-$C_6$ alkenyl, $C_2$-$C_6$ alkynyl, -Cyc, or –( $C_1$-$C_3$ alkyl)-Cyc wherein Cyc is optionally substituted monocyclic carbocyclic or heterocyclic having 3-7 ring atoms;

**Z** is N or CH, or CF;

$R_2$ is a group $Q^1$-[$Alk^1$]$_q$-$Q^2$ -, wherein

**q is** 0 or 1;

**$Alk^1$** is an optionally substituted, divalent, straight chain or branched $C_1$-$C_6$ alkylene, or $C_2$-$C_6$ alkenylene or $C_2$-$C_6$ alkynylene radical which may contain or terminate in an ether (-O-), thioether (-S-) or amino (-NR)- link;

**$Q^2$** is an optionally substituted divalent monocyclic carbocyclic or heterocyclic radical having 5 or 6 ring atoms or an optionally substituted divalent bicyclic carbocyclic or heterocyclic radical having 9 or 10 ring atoms;

**$Q^1$** is hydrogen, an optional substituent, or an optionally substituted carbocyclic or heterocyclic radical having 3-7 ring atoms;

$R_3$ is a group $Q^4$-$[Alk^2]_p$-$[Q^3]_q$- other than hydrogen wherein

**p** and **q** are independently 0 or 1;

**$Alk^2$** is optionally substituted divalent $C_1$-$C_6$ alkylene or $C_2$-$C_6$ alkenylene or $C_2$-$C_6$ alkynylene radical;

**$Q^3$** is an optionally substituted divalent monocyclic carbocyclic or heterocyclic radical having 5 or 6 ring atoms or an optionally substituted divalent bicyclic carbocyclic or heterocyclic radical having 9 or 10 ring atoms;

**$Q^4$** is hydrogen, an optional substituent, or optionally substituted carbocyclic or heterocyclic ring having 3-7 ring atoms.

2. The use as claimed in claim 1 wherein, in the said compound, Z is CH.

3. The use as claimed in claim 1 or claim 2 wherein, in the said compound, m is 1 and Q is hydrogen.

4. The use as claimed in any of the preceding claims wherein, in the said compound, X is –C(O)NH-.

5. The use as claimed in claim 1 or claim 2 wherein, in the said compound, m is 1, Q is hydrogen, Alk is $–CH_2CH_2$-, and X is –C(O)NH-.

6. The use as claimed in any of the preceding claims wherein, in the substituent $R_2$ of the said compound, $Q^2$ is an optionally substituted pyridine, pyrimidine, pyrazine or pyridine-2-one ring.

7. The use as claimed in any of claims 1 to 5 wherein, in the substituent $R_2$ of the said compound, $Q^2$ is an optionally substituted pyridine-3-yl ring, an optionally substituted pyrimidine-5-yl ring, an optionally substituted pyrazine-2-yl ring or an optionally substituted pyridine-2-one-4-yl ring.

8. The use as claimed in any of the preceding claims wherein, in the substituent $R_2$ of the said compound, optional substituents in $Q^2$ are selected from $CH_3$-, $CH_3O$-, -CN, and $-NH_2$.

9. The use as claimed in any of the preceding claims wherein, in the substituent $R_2$ of the said compound, $Alk^1$ is present and is an optionally substituted divalent $C_1$-$C_3$ alkylene radical

10. The use as claimed in any of claims 1 to 8 wherein, in the substituent $R_2$ of the said compound, $Alk^1$ is present and is an optionally substituted divalent $C_1$-$C_3$ alkylene radical which includes an –NH- link, or optionally terminates in an -NH- link to $Q^2$.

11. The use as claimed in claim 10 wherein $Alk^1$ is a divalent $C_2$-$C_3$ alkylene radical which terminates in an -NH- link to $Q^2$, and which is oxo-substituted on the C atom adjacent that –NH- link, whereby $Alk^1$ has the formula $-(CH_2)_{0-2}C(=O)NH-$.

12. The use as claimed in claim 10 wherein $Alk^1$ has the formula $-(CH_2)_{1-2}NHC(=O)-$, with the (C=O) being linked to $Q^2$.


13. The use as claimed in any of claims 9 to 12 wherein, in the substituent $R_2$ of the said compound, $Q^1$ is a primary, secondary or cyclic amino group.

14. The use as claimed in any of claims 9 to 12 wherein, in the substituent $R_2$ of the said compound, $Q^1$ is a group of formula $-NR^AR^B$, wherein $R^A$ and $R^B$ are independently hydrogen or a ($C_1$-$C_6$)alkyl, hydroxy($C_1$-$C_6$)alkyl, or ($C_1$-$C_3$)alkoxy($C_1$-$C_3$)alkyl group.

15. The use as claimed in any of claims 9 to 12 wherein, in the substituent $R_2$ of the said compound, $Q^1$ is a group of formula $-NR^AR^B$, wherein $R^A$ and $R^B$ taken together with that nitrogen form a cyclic amino ring.

16. The use as claimed in claim 15 wherein the cyclic amino ring is a morpholinyl, piperidinyl, or piperazinyl ring.

17. The use as claimed any of claims 1 to 5 wherein the substituent $R_2$ of the said compound is selected from the following radicals:



18. The use as claimed in any of the preceding claims wherein, in the substituent $R_3$ of the said compound, q is 1.

19. The use as claimed in claim 18 wherein, in the substituent $R_3$ of the said compound, p is 1.

20. The use as claimed in claim 19 wherein, in the substituent $R_3$ of the said compound, $Alk^2$ is an optionally substituted divalent $C_1$-$C_3$ alkylene radical.

21. The use as claimed in claim 18 wherein, in the substituent $R_3$ of the said compound, $Q^4$ is hydrogen and p is 0.


22. The use as claimed in any of claims 18 to 21 wherein, in the substituent $R_3$ of the said compound, $Q^3$ is an optionally substituted pyridine ring, an optionally substituted pyrimidine ring or an optionally substituted pyrazine ring.

23. The use as claimed in any of claims 18 to 21 wherein, in the substituent $R_3$ of the said compound, $Q^3$ is an optionally substituted pyridine-2-yl ring, an optionally substituted pyrimidine-2-yl ring or an optionally substituted pyrazine-2-yl ring.

24. The use as claimed in any of the preceding claims wherein, in the substituent $R_3$ of the said compound, optional substituents in $Q^3$ are selected from $CH_3O$-, -$NH_2$, -CN, Cl, $CH_3$-, and -$CF_3$

25. The use as claimed in any of claims 1 to 17 wherein, in the substituent $R_3$ of the said compound, p and q are 0 and $Q^4$ is selected from halo, -$CONHR^A$, -$NHCONHR^B$, wherein $R^A$ and $R^B$ are hydrogen or a ($C_1$-$C_6$)alkyl, hydroxy($C_1$-$C_6$)alkyl, or ($C_1$-$C_3$)alkoxy($C_1$-$C_3$)alkyl group.

26. The use as claimed any of claims 1 to 17 wherein the substituent $R_3$ of the said compound is selected from the following radicals:



27. A method of treating or preventing bacterial contamination of a substrate comprising applying to the site of such contamination or potential contamination an amount of a compound (I) as defined in any of claims 1 to 26, sufficient to inhibit bacterial growth

28. A method of treatment of a subject suffering a bacterial infection, or preventing bacterial infection in a subject, comprising administering to said subject an antibacterially effective amount of a compound as defined in any of claims 1 to 26.

29. A compound of formula (I) as defined in claim 1, or a salt, hydrate, solvate or N-oxide thereof, wherein, in the substituent $R_3$, q is 1.

30. A compound as claimed in claim 29 wherein Z is CH.

31. A compound as claimed in claim 29 or claim 30 wherein m is 1 and Q is hydrogen.

32. A compound as claimed in any of claims 29 to 31 wherein X is –C(O)NH-.

33. A compound as claimed in claim 29 or claim 30 wherein m is 1, Q is hydrogen, Alk is $–CH_2CH_2-$, and X is –C(O)NH-.

34. A compound as claimed in any of claims 29 to 33 wherein $Q^2$ is an optionally substituted pyridine, pyrimidine, or pyrazine ring or an optionally substituted pyridine-2-one ring.

35. A compound as claimed in any of claims 29 to 33 wherein $Q^2$ is an optionally substituted pyridine-3-yl ring, an optionally substituted pyrimidine-5-yl ring, an optionally substituted pyrazine-2-yl ring or an optionally substituted pyridine-2-one-4-yl ring.

36. A compound as claimed in any of claims 29 to 35 wherein optional substituents in $Q^2$ are selected from $CH_3-$, $CH_3O-$, -CN, and $-NH_2$.

37. A compound as claimed in any of claims 29 to 36 wherein $Alk^1$ is present and is an optionally substituted divalent $C_1$-$C_3$ alkylene radical

38. A compound as claimed in any of claims 29 to 34 wherein $Alk^1$ is present and is an optionally substituted divalent $C_1$-$C_3$ alkylene radical which includes an –NH- link, or optionally terminates in an -NH- link to $Q^2$.

39. A compound as claimed in claim 38 wherein $Alk^1$ is a divalent $C_2$-$C_3$ alkylene radical which terminates in an -NH- link to $Q^2$, and which is oxo-substituted on the C atom adjacent that –NH- link, whereby $Alk^1$ has the formula $–(CH_2)_{0\text{-}2}C(=O)NH$-.

40. A compound as claimed in claim 38 wherein $Alk^1$ has the formula $–(CH_2)_{1\text{-}2}NHC(=O)$-, with the (C=O) being linked to $Q^2$.


41. A compound as claimed in any of claims 37 to 39 wherein, in the substituent $R_2$ of the said compound, $Q^1$ is a primary, secondary or cyclic amino group.

42. A compound as claimed in any of claims 37 to 40 wherein $Q^1$ is a group of formula $-NR^AR^B$, wherein $R^A$ and $R^B$ are independently hydrogen or a ($C_1$-$C_6$)alkyl, hydroxy($C_1$-$C_6$)alkyl, or ($C_1$-$C_3$)alkoxy($C_1$-$C_3$)alkyl group.

43. A compound as claimed in any of claims 37 to 40 wherein $Q^1$ is a group of formula $-NR^AR^B$, wherein $R^A$ and $R^B$ taken together with that nitrogen form a cyclic amino ring.

44. A compound as claimed in claim 43 wherein the cyclic amino ring is a morpholinyl, piperidinyl, or piperazinyl ring.

45. A compound as claimed in any of claims 29 to 33 wherein $R_2$ is selected from the following radicals:



46. A compound as claimed in any of claims 29 to 45 wherein p is 1.

47. A compound as claimed in claim 46 wherein $Alk^2$ is an optionally substituted divalent $C_1$-$C_3$ alkylene radical.


48. A compound as claimed in any of claims 29 to 45 wherein $Q^4$ is hydrogen and p is 0.

49. A compound as claimed in any of claims 46 to 48 wherein $Q^3$ is an optionally substituted pyridine ring, an optionally substituted pyrimidine ring or an optionally substituted pyrazine ring.

50. A compound as claimed in any of claims 46 to 48 wherein $Q^3$ is an optionally substituted pyridine-2-yl ring, an optionally substituted pyrimidine-2-yl ring or an optionally substituted pyrazine-2-yl ring.

51. A compound as claimed in any of claims 29 to 50 wherein optional substituents in $Q^3$ are selected from $CH_3O$-, $-NH_2$, -CN, Cl, $CH_3$-, and $-CF_3$.

52. A compound as claimed in any of claims 29 to 45 wherein $R_3$ is selected from the following radicals:




53. A compound as claimed in claim 29 or claim 30 wherein m is 1, Q is hydrogen, Alk is $-CH_2CH_2-$, X is $-C(O)NH-$. $R_2$ is a radical selected from those specified in claim 45 and $R_3$ is a radical selected from those specified in claim 52.

54. A pharmaceutical composition comprising a compound as claimed in any of claims 29 to 53, together with a pharmaceutically acceptable carrier.

## Claims

1. The use of a compound of formula (I), or a salt, hydrate, solvate or N-oxide thereof, in the preparation of an antibacterial composition:




(I)

wherein:

**m** is 0 or 1;

**Q** is hydrogen or cyclopropyl;

**Alk** is an optionally substituted, divalent $C_1$-$C_6$ alkylene, alkenylene or alkynylene radical which may contain an ether (-O-), thioether (-S-) or amino (-NR)- link, wherein **R** is hydrogen, -CN or $C_1$-$C_3$ alkyl;

**X** is -C(=O)$NR_6$-, -S(O)$NR_6$-, -C(=O)O- or -S(=O)O- wherein $R_6$ is hydrogen, optionally substituted $C_1$-$C_6$ alkyl, $C_2$-$C_6$ alkenyl, $C_2$-$C_6$ alkynyl, -Cyc, or –( $C_1$-$C_3$ alkyl)-Cyc wherein Cyc is optionally substituted monocyclic carbocyclic or heterocyclic having 3-7 ring atoms;

**Z** is N or CH, or CF;

$R_2$ is a group $Q^1$-[$Alk^1$]$_q$-$Q^2$ -, wherein

**q is** 0 or 1;

**$Alk^1$** is an optionally substituted, divalent, straight chain or branched $C_1$-$C_6$ alkylene, or $C_2$-$C_6$ alkenylene or $C_2$-$C_6$ alkynylene radical which may contain or terminate in an ether (-O-), thioether (-S-) or amino (-NR)- link;

**$Q^2$** is an optionally substituted divalent monocyclic carbocyclic or heterocyclic radical having 5 or 6 ring atoms or an optionally substituted divalent bicyclic carbocyclic or heterocyclic radical having 9 or 10 ring atoms;

**$Q^1$** is hydrogen, an optional substituent, or an optionally substituted carbocyclic or heterocyclic radical having 3-7 ring atoms;

$R_3$ is a group $Q^4$-$[Alk^2]_p$-$[Q^3]_q$- other than hydrogen wherein

**p** and **q** are independently 0 or 1;

**$Alk^2$** is optionally substituted divalent $C_1$-$C_6$ alkylene or $C_2$-$C_6$ alkenylene or $C_2$-$C_6$ alkynylene radical;

**$Q^3$** is an optionally substituted divalent monocyclic carbocyclic or heterocyclic radical having 5 or 6 ring atoms or an optionally substituted divalent bicyclic carbocyclic or heterocyclic radical having 9 or 10 ring atoms;

**$Q^4$** is hydrogen, an optional substituent, or optionally substituted carbocyclic or heterocyclic ring having 3-7 ring atoms.

2. The use as claimed in claim 1 wherein, in the said compound, m is 1, Q is hydrogen, Alk is $-CH_2CH_2-$, and X is –C(O)NH-.

3. A compound of formula (I) as defined in claim 1, or a salt, hydrate, solvate or N-oxide thereof, wherein, in the substituent $R_3$, q is 1.

4. A compound as claimed in claim 3 wherein Z is CH.

5. A compound as claimed in claim 3 or 4 wherein m is 1, Q is hydrogen, Alk is $-CH_2CH_2-$, and X is –C(O)NH-.

6. A compound as claimed in any of claims 3 to 5 wherein $Q^2$ is an optionally substituted pyridine, pyrimidine, or pyrazine ring or an optionally substituted pyridine-2-one ring.

7. A compound as claimed in any of claims 3 to 6 wherein optional substituents in $Q^2$ are selected from $CH_3$-, $CH_3O$-, -CN, and $-NH_2$.

8. A compound as claimed in any of claims 3 to 7 wherein $Alk^1$ is present and is an optionally substituted divalent $C_1$-$C_3$ alkylene radical

9. A compound as claimed in any of claims 3 to 6 wherein $Alk^1$ is present and is an optionally substituted divalent $C_1$-$C_3$ alkylene radical which includes an –NH- link, or optionally terminates in an -NH- link to $Q^2$.


10. A compound as claimed in claim 9 wherein $Alk^1$ is a divalent $C_2$-$C_3$ alkylene radical which terminates in an -NH- link to $Q^2$, and which is oxo-substituted on the C atom adjacent that –NH- link, whereby $Alk^1$ has the formula $-(CH_2)_{0-2}C(=O)NH-$.

11. A compound as claimed in claim 9 wherein $Alk^1$ has the formula $-(CH_2)_{1-2}NHC(=O)-$, with the (C=O) being linked to $Q^2$.

12. A compound as claimed in any of claims 8 to 11 wherein $Q^1$ is a group of formula $-NR^AR^B$, wherein $R^A$ and $R^B$ are independently hydrogen or a $(C_1$-$C_6)$alkyl, hydroxy$(C_1$-$C_6)$alkyl, or $(C_1$-$C_3)$alkoxy$(C_1$-$C_3)$alkyl group.

13. A compound as claimed in any of claims 8 to 11 wherein $Q^1$ is a group of formula $-NR^AR^B$, wherein $R^A$ and $R^B$ taken together with that nitrogen form a cyclic amino ring selected from a morpholinyl, piperidinyl, piperazinyl or 4-$(C_{1-6}$allyl) piperazinyl ring.

14. A compound as claimed in any of claims 3 to 5 wherein $R_2$ is selected from the following radicals:



15. A compound as claimed in any of claims 3 to 14 wherein p is 1.


16. A compound as claimed in claim 15 wherein $Alk^2$ is an optionally substituted divalent $C_1$-$C_3$ alkylene radical.

17. A compound as claimed in any of claims 3 to 14 wherein $Q^4$ is hydrogen and p is 0.

18. A compound as claimed in any of claims 15 to 17 wherein $Q^3$ is an optionally substituted pyridine ring, an optionally substituted pyrimidine ring or an optionally substituted pyrazine ring.

19. A compound as claimed in any of claims 3 to 18 wherein optional substituents in $Q^3$ are selected from $CH_3O$-, -$NH_2$, -CN, Cl, $CH_3$-, and -$CF_3$.

20. A compound as claimed in any of claims 3 to 14 wherein $R_3$ is selected from



the following radicals:

21. A compound as claimed in claim 3, selected from the group consisting of:

1-(5,7-Di-pyridin-3-yl-benzothiazol-2-yl)-3-ethyl-urea;

1-[5,7-Bis-(1-methyl-1H-pyrazol-4-yl)-benzothiazol-2-yl]-3-ethyl-urea ;

1-(5,7-Di-pyrazin-2-yl-benzothiazol-2-yl)-3-ethyl-urea;

1-Ethyl-3-[7-(1-methyl-1H-pyrrol-2-yl)-5-pyridin-3-yl-benzothiazol-2-yl]-urea;

1-Ethyl-3-(5-pyrazol-1-yl-7-pyridin-3-yl-benzothiazol-2-yl)-urea;

1-Ethyl-3-(7-pyridin-3-yl-5-pyrimidin-5-yl-benzothiazol-2-yl)-urea;
1-[5-(2-Amino-pyrimidin-5-yl)-7-pyridin-3-yl-benzothiazol-2-yl]-3-ethyl-urea;

1-Ethyl-3-[5-(2-methoxy-pyrimidin-5-yl)-7-pyridin-3-yl-benzothiazol-2-yl]-urea;

1-Ethyl-3-[5-(6-hydroxy-pyridin-3-yl)-7-pyridin-3-yl-benzothiazol-2-yl]-urea;

1-[5-(6-Amino-pyridin-3-yl)-7-pyridin-3-yl-benzothiazol-2-yl]-3-ethyl-urea;

1-Ethyl-3-[5-(4-hydroxymethyl-phenyl)-7-pyridin-3-yl-benzothiazol-2-yl]-urea;

1-Ethyl-3-[5-(6-hydroxymethyl-pyridin-3-yl)-7-pyridin-3-yl-benzothiazol-2-yl]-urea;

*N*-{5-[2-(3-Ethyl-ureido)-7-pyridin-3-yl-benzothiazol-5-yl]-pyridin-2-yl}-acetamide;

1-Ethyl-3-[5-(4-morpholin-4-ylmethyl-phenyl)-7-pyridin-3-yl-benzothiazol-2-yl]-urea;

1-Ethyl-3-(5-imidazo[1,2-*a*]pyridin-6-yl-7-pyridin-3-yl-benzothiazol-2-yl)-urea;

1-Ethyl-3-{5-[6-(4-methyl-piperazin-1-yl)-pyridin-3-yl]-7-pyridin-3-yl-benzothiazol-2-yl}-urea;

1-[5-(5-Cyano-pyridin-3-yl)-7-pyridin-3-yl-benzothiazol-2-yl]-3-ethyl-urea;

1-[5-(2-Dimethylamino-pyrimidin-5-yl)-7-pyridin-3-yl-benzothiazol-2-yl]-3-ethyl-urea;

5-[2-(3-Ethyl-ureido)-7-pyridin-3-yl-benzothiazol-5-yl]-pyridine-2-carboxylic acid methyl ester;

1-[5-(6-Cyano-pyridin-3-yl)-7-pyridin-3-yl-benzothiazol-2-yl]-3-ethyl-urea;

1-Ethyl-3-[5-(3-fluoro-phenyl)-7-pyridin-3-yl-benzothiazol-2-yl]-urea;

1-Ethyl-3-[5-(6-methoxy-pyridin-3-yl)-7-pyridin-3-yl-benzothiazol-2-yl]-urea;

1-Ethyl-3-(5-pyridin-4-yl-7-pyridin-3-yl-benzothiazol-2-yl)-urea;

1-Ethyl-3-[5-(5-methoxy-pyridin-3-yl)-7-pyridin-3-yl-benzothiazol-2-yl]-urea;

1-[5-(2-Cyano-pyrimidin-5-yl)-7-pyridin-3-yl-benzothiazol-2-yl]-3-ethyl-urea;

1-[5-(6-Cyano-pyridin-3-yl)-7-pyridin-2-yl-benzothiazol-2-yl]-3-ethyl-urea;

1-Ethyl-3-[5-(6-hydroxymethyl-pyridin-3-yl)-7-pyridin-2-yl-benzothiazol-2-yl]-urea;

1-Ethyl-3-(7-pyridin-2-yl-5-pyrimidin-5-yl-benzothiazol-2-yl)-urea;

1-Ethyl-3-[5-(5-methyl-pyridin-3-yl)-7-pyridin-2-yl-benzothiazol-2-yl]-urea;

1-Ethyl-3-(5-furan-3-yl-7-pyridin-2-yl-benzothiazol-2-yl)-urea;

1-[5-(6-Dimethylamino-pyridin-3-yl)-7-pyridin-2-yl-benzothiazol-2-yl]-3-ethyl-urea;

1-Ethyl-3-[5-(4-methyl-pyridin-3-yl)-7-pyridin-2-yl-benzothiazol-2-yl]-urea;

1-Ethyl-3-[5-(2-methoxy-pyridin-4-yl)-7-pyridin-2-yl-benzothiazol-2-yl]-urea;

1-Ethyl-3-[5-(6-methyl-pyridin-3-yl)-7-pyridin-2-yl-benzothiazol-2-yl]-urea

1-[7-(2-Amino-pyrimidin-5-yl)-5-pyridin-3-yl-benzothiazol-2-yl]-3-ethyl-urea;

1-Ethyl-3-(5-pyrazin-2-yl-7-pyridin-3-yl-benzothiazol-2-yl)-urea;

1-[5-(4-Amino-pyridin-3-yl)-7-pyridin-3-yl-benzothiazol-2-yl]-3-ethyl-urea;

1-[5-(6-Amino-pyrazin-2-yl)-7-pyridin-3-yl-benzothiazol-2-yl]-3-ethyl-urea;

1-Ethyl-3-[5-(6-methyl-pyridazin-3-yl)-7-pyridin-3-yl-benzothiazol-2-yl]-urea;

1-Ethyl-3-[5-(1-methyl-2-oxo-1,2-dihydro-pyridin-4-yl)-7-pyridin-3-yl-benzothiazol-2-yl]-urea;

1-[5-(5-Chloro-pyridin-3-yl)-7-pyridin-3-yl-benzothiazol-2-yl]-3-ethyl-urea;

1-Ethyl-3-[7-pyridin-3-yl-5-(1*H*-pyrrolo[2,3-*b*]pyridin-5-yl)-benzothiazol-2-yl]-urea;

1-[5-(1,6-Dimethyl-2-oxo-1,2-dihydro-pyridin-4-yl)-7-pyridin-3-yl-benzothiazol-2-yl]-3-ethyl-urea;)

1-Ethyl-3-[5-(1-methyl-2-oxo-1,2-dihydro-pyridin-4-yl)-7-pyridin-2-yl-benzothiazol-2-yl]-urea;

1-Ethyl-3-[5-(2-methyl-pyridin-3-yl)-7-pyridin-2-yl-benzothiazol-2-yl]-urea;)

1-[5-(6-Amino-pyrazin-2-yl)-7-pyridin-2-yl-benzothiazol-2-yl]-3-ethyl-urea;

1-Ethyl-3-[5-(2-oxo-2,3-dihydro-1*H*-pyrido[2,3-*b*][1,4]oxazin-7-yl)-7-pyridin-2-yl-benzothiazol-2-yl]-urea;

2-*tert*-Butylamino-*N*-{5-[2-(3-ethyl-ureido)-7-pyridin-2-yl-benzothiazol-5-yl]-pyridin-2-yl}-acetamide;

1-Ethyl-3-[5-(2-hydroxy-pyridin-4-yl)-7-pyridin-2-yl-benzothiazol-2-yl]-urea;

1-Ethyl-3-{5-[1-(2-hydroxy-ethyl)-2-oxo-1,2-dihydro-pyridin-4-yl]-7-pyridin-2-yl-benzothiazol-2-yl}-urea;

1-Ethyl-3-{5-[6-(2-hydroxy-ethyl)-pyridin-3-yl]-7-pyridin-2-yl-benzothiazol-2-yl}-urea (58)

1-Ethyl-3-[5-(6-morpholin-4-ylmethyl-pyridin-3-yl)-7-pyridin-2-yl-benzothiazol-2-yl]-urea;

1-[5-(6-{[Bis-(2-methoxy-ethyl)-amino]-methyl}-pyridin-3-yl)-7-pyridin-2-yl-benzothiazol-2-yl]-3-ethyl-urea;

1-{5-[6-(2-Dimethylamino-ethylamino)-pyridin-3-yl]-7-pyridin-2-yl-benzothiazol-2-yl}-3-ethyl-urea;

1-Ethyl-3-{5-[5-(4-methyl-piperazin-1-yl)-pyridin-3-yl]-7-pyridin-2-yl-benzothiazol-2-yl}-urea;

1-Ethyl-3-{5-[1-(2-morpholin-4-yl-ethyl)-2-oxo-1,2-dihydro-pyridin-4-yl]-7-pyridin-2-yl-benzothiazol-2-yl}-urea;

*N*-(2-Dimethylamino-ethyl)-5-[2-(3-ethyl-ureido)-7-pyridin-2-yl-benzothiazol-5-yl]-nicotinamide;

1-Ethyl-3-[7-pyridin-2-yl-5-(5,6,7,8-tetrahydro-[1,6]naphthyridin-3-yl)-benzothiazol-2-yl]-urea;

2-Dimethylamino-*N*-{5-[2-(3-ethyl-ureido)-7-pyridin-2-yl-benzothiazol-5-yl]-pyridin-2-yl}-acetamide;

1-Ethyl-3-[5-(6-methylaminomethyl-pyridin-3-yl)-7-pyridin-2-yl-benzothiazol-2-yl]-urea;

5-[2-(3-Ethyl-ureido)-7-pyridin-2-yl-benzothiazol-5-yl]-*N*-(2-morpholin-4-yl-ethyl)-nicotinamide;

{5-[2-(3-Ethyl-ureido)-7-pyridin-2-yl-benzothiazol-5-yl]-pyridin-2-yl}-acetic acid methyl ester;

2-{5-[2-(3-Ethyl-ureido)-7-pyridin-2-yl-benzothiazol-5-yl]-pyridin-2-yl}-*N*-methyl-acetamide;

1-Ethyl-3-[5-(7-oxo-5,6,7,8-tetrahydro-[1,8]naphthyridin-3-yl)-7-pyridin-2-yl-benzothiazol-2-yl]-urea;

1-{5-[1-(2-Dimethylamino-ethyl)-2-oxo-1,2-dihydro-pyridin-4-yl]-7-pyridin-2-yl-benzothiazol-2-yl}-3-ethyl-urea;

1-[7-(2-Amino-pyrimidin-5-yl)-5-pyrazin-2-yl-benzothiazol-2-yl]-3-ethyl-urea;

1-[7-(2-Amino-pyrimidin-5-yl)-5-pyridin-2-yl-benzothiazol-2-yl]-3-ethyl-urea;

1-Ethyl-3-[7-(2-fluoro-phenyl)-5-pyridin-3-yl-benzothiazol-2-yl]-urea;

1-Ethyl-3-[7-(2-fluoro-pyridin-3-yl)-5-pyridin-3-yl-benzothiazol-2-yl]-urea;

1-Ethyl-3-(5-pyridin-3-yl-7-thiophen-3-yl-benzothiazol-2-yl)-urea;

1-Ethyl-3-(7-phenyl-5-pyridin-3-yl-benzothiazol-2-yl)-urea;

1-(7-Cyclopropyl-5-pyridin-3-yl-benzothiazol-2-yl)-3-ethyl-urea;

1-Ethyl-3-[7-(1H-pyrazol-4-yl)-5-pyridin-3-yl-benzothiazol-2-yl]-urea;

1-Ethyl-3-{7-[1-(2-morpholin-4-yl-ethyl)-1H-pyrazol-4-yl]-5-pyridin-3-yl-benzothiazol-2-yl}-urea;

1-Ethyl-3-[7-(1H-pyrazol-3-yl)-5-pyridin-3-yl-benzothiazol-2-yl]-urea;

1-Ethyl-3-[7-(1-methyl-1H-pyrazol-4-yl)-5-pyridin-3-yl-benzothiazol-2-yl]-urea;

1-Ethyl-3-[7-(4-methoxy-phenyl)-5-pyridin-3-yl-benzothiazol-2-yl]-urea;

1-Ethyl-3-[7-(2-methoxy-pyridin-3-yl)-5-pyridin-3-yl-benzothiazol-2-yl]-urea;

1-Ethyl-3-[7-(3-methoxy-phenyl)-5-pyridin-3-yl-benzothiazol-2-yl]-urea;

1-Ethyl-3-[7-(2-methoxy-phenyl)-5-pyridin-3-yl-benzothiazol-2-yl]-urea;

1-[7-(6-Chloro-pyridin-2-yl)-5-pyridin-3-yl-benzothiazol-2-yl]-3-ethyl-urea;

1-Ethyl-3-[5-pyridin-3-yl-7-(6-trifluoromethyl-pyridin-2-yl)-benzothiazol-2-yl]-urea;

1-Ethyl-3-[5-pyridin-3-yl-7-(1H-pyrrol-2-yl)-benzothiazol-2-yl]-urea;

1-Ethyl-3-[7-(3-fluoro-pyridin-2-yl)-5-pyridin-3-yl-benzothiazol-2-yl]-urea;

1-Ethyl-3-(5-pyridin-3-yl-7-thiazol-2-yl-benzothiazol-2-yl)-urea;

1-Ethyl-3-(5-pyridin-3-yl-7-pyrimidin-2-yl-benzothiazol-2-yl)-urea;

1-[7-(3-Amino-pyridin-2-yl)-5-pyridin-3-yl-benzothiazol-2-yl]-3-ethyl-urea;

1-[7-(3-Cyano-pyridin-2-yl)-5-pyridin-3-yl-benzothiazol-2-yl]-3-ethyl-urea;

1-Ethyl-3-[7-(5-hydroxymethyl-pyridin-2-yl)-5-pyridin-3-yl-benzothiazol-2-yl]-urea;

1-[7-(5-Aminomethyl-pyridin-2-yl)-5-pyridin-3-yl-benzothiazol-2-yl]-3-ethyl-urea;

6-[2-(3-Ethyl-ureido)-5-pyridin-3-yl-benzothiazol-7-yl]-nicotinamide;

1-[7-(5-Amino-pyridin-2-yl)-5-pyridin-3-yl-benzothiazol-2-yl]-3-ethyl-urea;

1-[7-(4-Amino-pyridin-2-yl)-5-pyridin-3-yl-benzothiazol-2-yl]-3-ethyl-urea;

1-Ethyl-3-(7-pyrazin-2-yl-5-pyridin-3-yl-benzothiazol-2-yl)-urea;

1-[7-(2,4-Dimethyl-thiazol-5-yl)-5-pyridin-3-yl-benzothiazol-2-yl]-3-ethyl-urea;

1-[7-(3-Cyano-6-methyl-pyridin-2-yl)-5-pyridin-3-yl-benzothiazol-2-yl]-3-ethyl-urea;

1-Ethyl-3-[7-(6-hydroxymethyl-pyridin-2-yl)-5-pyridin-3-yl-benzothiazol-2-yl]-urea;

1-Ethyl-3-[7-(6-methoxy-pyridazin-3-yl)-5-pyridin-3-yl-benzothiazol-2-yl]-urea;

1-Ethyl-3-[7-(4-hydroxymethyl-thiazol-2-yl)-5-pyridin-3-yl-benzothiazol-2-yl]-urea;

1-[7-(5-Cyano-pyridin-2-yl)-5-pyridin-3-yl-benzothiazol-2-yl]-3-ethyl-urea;

2-[2-(3-Ethyl-ureido)-5-pyridin-3-yl-benzothiazol-7-yl]-isonicotinamide;

1-Ethyl-3-[7-(3-hydroxymethyl-pyridin-2-yl)-5-pyridin-3-yl-benzothiazol-2-yl]-urea;

1-[7-(4-Amino-pyrimidin-2-yl)-5-pyridin-3-yl-benzothiazol-2-yl]-3-ethyl-urea;

1-Ethyl-3-[5-pyridin-3-yl-7-(1*H*-pyrrolo[2,3-*b*]pyridin-6-yl)-benzothiazol-2-yl]-urea;

1-Ethyl-3-[7-(4-methoxy-pyridin-2-yl)-5-pyridin-3-yl-benzothiazol-2-yl]-urea;

1-[7-(6-Cyano-pyridin-2-yl)-5-pyridin-3-yl-benzothiazol-2-yl]-3-ethyl-urea;

1-[7-(2-Amino-pyrimidin-4-yl)-5-pyridin-3-yl-benzothiazol-2-yl]-3-ethyl-urea;

1-Ethyl-3-[5-pyridin-3-yl-7-(1*H*-pyrrolo[2,3-*c*]pyridin-7-yl)-benzothiazol-2-yl]-urea;

1-Ethyl-3-[5-pyridin-3-yl-7-(7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl)-benzothiazol-2-yl]-urea;

1-Ethyl-3-(5'-pyridin-3-yl-[2,7']bibenzothiazolyl-2'-yl)-urea;

1-Ethyl-3-[7-(3-methoxy-pyridin-2-yl)-5-pyridin-3-yl-benzothiazol-2-yl]-urea;

1-[7-(4-Cyano-pyridin-2-yl)-5-pyridin-3-yl-benzothiazol-2-yl]-3-ethyl-urea;

1-Ethyl-3-[7-(5-morpholin-4-ylmethyl-pyridin-2-yl)-5-pyridin-3-yl-benzothiazol-2-yl]-urea;

1-Ethyl-3-[7-(4-hydroxymethyl-pyridin-2-yl)-5-pyridin-3-yl-benzothiazol-2-yl]-urea;

1-Ethyl-3-[7-(6-methoxy-pyrimidin-4-yl)-5-pyridin-3-yl-benzothiazol-2-yl]-urea;

1-[7-(6-Amino-pyrazin-2-yl)-5-pyridin-3-yl-benzothiazol-2-yl]-3-ethyl-urea;

1-Ethyl-3-[7-(4-methoxy-pyrimidin-2-yl)-5-pyridin-3-yl-benzothiazol-2-yl]-urea;

1-[7-(6-Amino-pyridin-2-yl)-5-pyridin-3-yl-benzothiazol-2-yl]-3-ethyl-urea;

1-[7-(3-Chloro-pyridin-2-yl)-5-pyridin-3-yl-benzothiazol-2-yl]-3-ethyl-urea;

1-[7-(4-Chloro-pyridin-2-yl)-5-pyridin-3-yl-benzothiazol-2-yl]-3-ethyl-urea;

1-Ethyl-3-[5-pyridin-3-yl-7-(3-trifluoromethyl-pyridin-2-yl)-benzothiazol-2-yl]-urea;

1-Ethyl-3-[5-pyridin-3-yl-7-(5-trifluoromethyl-pyridin-2-yl)-benzothiazol-2-yl]-urea;

1-[7-(5-Chloro-pyridin-2-yl)-5-pyridin-3-yl-benzothiazol-2-yl]-3-ethyl-urea;

1-[7-(5-Amino-pyrazin-2-yl)-5-pyridin-3-yl-benzothiazol-2-yl]-3-ethyl-urea;

1-[7-(5-Dimethylaminomethyl-pyridin-2-yl)-5-pyridin-3-yl-benzothiazol-2-yl]-3-ethyl-urea;

*N*-{5-[2-(3-Ethyl-ureido)-7-pyridin-2-yl-benzothiazol-5-yl]-pyridin-2-yl}-acetamide;

*N*-{5-[2-(3-Ethyl-ureido)-7-pyrazin-2-yl-benzothiazol-5-yl]-pyridin-2-yl}-acetamide;

*N*-{5-[7-(5-Amino-pyridin-2-yl)-2-(3-ethyl-ureido)-benzothiazol-5-yl]-pyridin-2-yl}-acetamide;

*N*-{5-[7-(5-Cyano-pyridin-2-yl)-2-(3-ethyl-ureido)-benzothiazol-5-yl]-pyridin-2-yl}-acetamide;

*N*-{5-[2-(3-Ethyl-ureido)-7-(1*H*-pyrrolo[2,3-*c*]pyridin-7-yl)-benzothiazol-5-yl]-pyridin-2-yl}-acetamide;

1-[5-(6-Amino-pyridin-3-yl)-7-pyridin-2-yl-benzothiazol-2-yl]-3-ethyl-urea;

1-[5-(2-Amino-pyrimidin-5-yl)-7-pyrazin-2-yl-benzothiazol-2-yl]-3-ethyl-urea;

1-Ethyl-3-(7-pyrazol-1-yl-5-pyridin-3-yl-benzothiazol-2-yl)-urea;

1-Ethyl-3-[5-(2-oxo-2*H*-pyridin-1-yl)-7-pyridin-3-yl-benzothiazol-2-yl]-urea;

1-Ethyl-3-(5-imidazol-1-yl-7-pyridin-2-yl-benzothiazol-2-yl)-urea;

1-[5,7-Bis-(5-methoxy-pyridin-3-yl)-benzothiazol-2-yl]-3-ethyl-urea;

1-[5,7-Bis-(4-hydroxymethyl-phenyl)-benzothiazol-2-yl]-3-ethyl-urea;

1-[5,7-Bis-(2-amino-pyrimidin-5-yl)-benzothiazol-2-yl]-3-ethyl-urea;

1-[5,7-Bis-(4-morpholin-4-ylmethyl-phenyl)-benzothiazol-2-yl]-3-ethyl-urea;

1-(5,7-Di-pyrimidin-5-yl-benzothiazol-2-yl)-3-ethyl-urea;

*N*-{5-[7-(6-Acetylamino-pyridin-3-yl)-2-(3-ethyl-ureido)-benzothiazol-5-yl]-pyridin-2-yl}-acetamide;

1-(7-Amino-5-pyridin-3-yl-benzothiazol-2-yl)-3-ethyl-urea;

1-Ethyl-3-[2-(3-ethyl-ureido)-5-pyridin-3-yl-benzothiazol-7-yl]-urea;

2-(3-Ethyl-ureido)-5-pyridin-3-yl-benzothiazole-7-carboxylic acid methyl ester. [Example 151]

2-(3-Ethyl-ureido)-5-pyridin-3-yl-benzothiazole-7-carboxylic acid ethylamide;

1-Ethyl-3-(7-hydrazinocarbonyl-5-pyridin-3-yl-benzothiazol-2-yl)-urea;

1-Ethyl-3-[5-(5-methoxy-pyridin-3-yl)-7-pyridin-2-yl-benzothiazol-2-yl]-urea;

1-[5-(2-Amino-pyrimidin-5-yl)-7-pyridin-2-yl-benzothiazol-2-yl]-3-ethyl-urea;

1-(7-Allyl-5-pyridin-3-yl-benzothiazol-2-yl)-3-ethyl-urea;

1-Ethyl-3-[7-(2-methoxy-thiazol-4-yl)-5-pyridin-3-yl-benzothiazol-2-yl]-urea;

1-Ethyl-3-(5-pyridin-3-yl-7-thiazol-4-yl-benzothiazol-2-yl)-urea;

1-Ethyl-3-(5-pyridin-3-yl-7-pyrimidin-5-yl-benzothiazol-2-yl)-urea;

1-Ethyl-3-(7-pyridazin-3-yl-5-pyridin-3-yl-benzothiazol-2-yl)-urea;

1-Ethyl-3-(5-pyridin-3-yl-7-thiazol-5-yl-benzothiazol-2-yl)-urea;

1-Ethyl-3-[7-(1-methyl-1H-imidazol-2-yl)-5-pyridin-3-yl-benzothiazol-2-yl]-urea;

1-Ethyl-3-(5-pyridin-3-yl-7-pyridin-2-yl-benzothiazol-2-yl)-urea;

1-Ethyl-3-[7-(3-methyl-3H-imidazol-4-yl)-5-pyridin-3-yl-benzothiazol-2-yl]-urea;

1-Ethyl-3-(7-oxazol-2-yl-5-pyridin-3-yl-benzothiazol-2-yl)-urea;

1-Ethyl-3-[7-(6-morpholin-4-yl-pyridin-2-yl)-5-pyridin-3-yl-benzothiazol-2-yl]-urea;

1-Ethyl-3-[7-(6-methoxy-pyridin-2-yl)-5-pyridin-3-yl-benzothiazol-2-yl]-urea;

1-[7-(6-Dimethylamino-pyridin-2-yl)-5-pyridin-3-yl-benzothiazol-2-yl]-3-ethyl-urea;

1-[7-(4-Dimethylamino-pyridin-2-yl)-5-pyridin-3-yl-benzothiazol-2-yl]-3-ethyl-urea;

1-(4,6-Dipyridin-2-yl benzothiazol-2-yl) 3-ethylurea;

1-Ethyl-3-[7-(2-hydroxy-thiazol-4-yl)-5-pyridin-3-yl-benzothiazol-2-yl]-urea;

1-Ethyl-3-[7-(6-hydroxy-pyridin-2-yl)-5-pyridin-3-yl-benzothiazol-2-yl]-urea;

(5-Pyridin-3-yl-7-pyridin-2-yl-benzothiazol-2-yl)-carbamic acid ethyl ester;

1-Ethyl-3-[7-(5-methyl-pyridin-2-yl)-5-pyridin-3-yl-benzothiazol-2-yl]-urea;

1-Ethyl-3-[7-(4-methyl-pyridin-2-yl)-5-pyridin-3-yl-benzothiazol-2-yl]-urea;

1-Ethyl-3-[7-(6-methyl-pyridin-2-yl)-5-pyridin-3-yl-benzothiazol-2-yl]-urea;

and salts, hydrates, solvates and N-oxides thereof.

22. Use of a compound of formula (I) as defined in any one of claims 3 to 21 or a salt, hydrate, solvate or N-oxide thereof in the preparation of an antibacterial composition.

23. A method of treating or preventing bacterial contamination of a substrate comprising applying to the site of such contamination or potential contamination an amount of a compound (I) as defined in any of claims 3 to 21, sufficient to inhibit bacterial growth.

24. A method of treatment of a subject suffering a bacterial infection, or preventing bacterial infection in a subject, comprising administering to said subject an antibacterially effective amount of a compound as defined in any of claims 3 to 21.

25. A pharmaceutical composition comprising a compound as claimed in any of claims 3 to 21, together with a pharmaceutically acceptable carrier.